The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy by Olafuyi, Olusola et al.
BDD-17-0050.R1 
 
The application of physiologically-based pharmacokinetic modelling to assess the impact of 1 
antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during 2 
pregnancy 3 
 4 
  5 
BDD-17-0050.R1 
 
ABSTRACT                    6 
Antimalarial therapy during pregnancy poses important safety concerns due to potential 7 
teratogenicity and maternal physiological and biochemical changes during gestation.  Piperaquine 8 
(PQ) has gained interest for use in pregnancy in response to increasing resistance towards 9 
sulfadoxine–pyrimethamine in sub-Saharan Africa.  Co-infection with HIV is common in many 10 
developing countries, however, little is known about the impact of anti-retroviral (ARV) mediated 11 
drug-drug interaction (DDI) on PQ pharmacokinetics during pregnancy.  This study applied 12 
mechanistic pharmacokinetic modelling to predict pharmacokinetics in non-pregnant and pregnant 13 
patients, which was validated in distinct customised population groups from Thailand, Sudan and 14 
Papua New Guinea.   In each population group, no significant difference in day 7 concentrations 15 
were observed during different gestational weeks (GW) (weeks 10-40), supporting the notion that 16 
PQ is safe throughout pregnancy with consistent pharmacokinetics, although possible 17 
teratogenicity may limit this.  Antiretroviral-mediated DDIs (efavirenz and ritonavir) had moderate 18 
effects on PQ during different gestational weeks with a predicted AUCratio ranging from 0.56-0.8 19 
and 1.64-1.79 for efavirenz and ritonavir respectively over GW 10-40, with a reduction in 20 
circulating human serum albumin significantly reducing the number of subjects attaining the day 7 21 
(post-dose) therapeutic efficacy concentrations under both efavirenz and ritonavir DDIs.   22 
This present model successfully mechanistically predicted the pharmacokinetics of PQ in 23 
pregnancy to be unchanged with respect to non-pregnant women, in the light of factors such as 24 
malaria/HIV co-infection. However, ART-mediated DDIs could significantly alter PQ 25 
pharmacokinetics. Further model refinement will include collation of relevant physiological and 26 
biochemical alterations common to HIV/malaria patients.  27 
  28 
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1. INTRODUCTION 33 
The problem of malaria-induced maternal morbidity and mortality in endemic areas for the disease 34 
is far reaching, particularly with respect to the unborn child. Maternal death due to malaria was 35 
reported to account for up to 25% of  maternal deaths due to all causes in malaria endemic regions 36 
while close to a million children born to malaria-infected mothers had low birth weights 37 
(Consortium, 2017).  38 
Malarial infection in pregnancy triples the maternal risk of suffering from severe diseases compared 39 
with non-pregnant women (Murray & Bennett, 2009).  This is further confounded by the added 40 
complication of coinfection with human immunodeficiency virus (HIV) as a result of the 41 
immunocompromised nature of pregnancy (Menendez et al., 2008; Ofori et al., 2009; Schantz-42 
Dunn & Nour, 2009).  43 
The treatment of malaria during pregnancy possess major challenges to healthcare systems. This is 44 
because antimalarial treatments (AMT) which yields satisfactory safety and efficacy profiles are 45 
often found to be unsafe during the early stages of pregnancy (Nosten et al., 2006). The WHO’s 46 
current recommendations for AMT chemoprophylaxis are based on intermittent preventive 47 
treatment with sulfadoxine-pyrimethamine (IPTp-SP) (Organization., 2015). This recommendation 48 
was based on a review (Kayentao et al., 2013) of seven trials which assessed the use of monthly 49 
SP administration for malaria prevention in pregnant women across six African countries.  The 50 
result of the review demonstrated that there was a significant reduction in both low birth weights 51 
and placental and maternal parasitaemia following administration of no less than two doses of SP 52 
monthly during pregnancy (Kayentao et al., 2013). 53 
However, with the spread of SP resistance, new interventions have been sought.  In high 54 
transmission settings where there may be widespread resistance to SP-IPTp, dihydroarteminisin-55 
piperaquine (DHA-PQ) has been demonstrated to result in a lower malarial burden (Kakuru et al., 56 
2016). A recent study showed that, when compared to the use of SP in pregnant women, the 57 
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administration of DHA-PQ provided significantly higher protection against placental malaria; 58 
significantly lowered maternal parasitaemia and reduced prevalence of composite adverse birth 59 
consequences (Kakuru et al., 2016). More so, the safety of DHA-PQ in pregnancy is evident in 60 
numerous studies. In 2015, a randomised controlled superiority trial showed that in addition to the 61 
observed efficacy of DHA-PQ for the preventing malaria in pregnancy, DHA-PQ resulted in fewer 62 
detrimental maternal and infant side effects compared with SP-IPTp (Desai et al., 2015). Similarly, 63 
another study revealed that compared to quinine, DHA-PQ used for the treatment of multi-resistant 64 
malaria in 2nd and 3rd trimester of pregnancy resulted in less perinatal mortality, though in the 1st 65 
trimester, quinine appeared to be safer (Poespoprodjo et al., 2014).   66 
Infectious diseases such as HIV are prevalent in malaria endemic regions (Benjamin et al., 2015; 67 
Tarning et al., 2012). Pregnant women with HIV and malaria coinfection are more vulnerable to 68 
all the complications of malaria in pregnancy such as anaemia, placental parasitaemia and low birth 69 
weights (Hayes et al., 2015). This can be further confounded by the potential for many antiretroviral 70 
(ART) drugs to elicit drug-drug interactions (DDIs) on common Cytochrome P450 isozymes, e.g. 71 
3A4 (Fichtenbaum & Gerber, 2002; Horita & Doi, 2014; Renjifo et al., 2015). Hence, these factors 72 
are significant causes for concern when treating this population. The reduced systemic 73 
concentration of DHA-PQ, due to co-administration with efavirenz in HIV infected pregnant 74 
women, has been demonstrated in a recent study which showed that in Ugandan pregnant women, 75 
AUC0-8hr and AUC0-21d  of piperaquine was 50% and 40% lower respectively when DHA-PQ was 76 
co-administered with efavirenz compared to when DHA-PQ was taken alone (Kajubi et al., 2017a). 77 
A systemic review of data involving DDI between ARV drugs and AMT further accentuated the 78 
likelihood of a range of such DDIs (Seden et al., 2017).  79 
Addressing the problem of AMT in malaria endemic areas requires consideration of physiological 80 
peculiarities in subjects that might impact upon the efficacy of the antimalarial treatment. Some 81 
example of factors that can impact upon the efficacy of AMT include, but not limited to, 82 
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geographical region differences in body weight (Hayes et al., 2015) and biochemistry (e.g serum 83 
albumin (Nanjul, 2007) and haematocrit (Newton et al., 2013; Othman, 2014)). Elucidating these 84 
factors individually in a clinical setting may be difficult due to the presence of other confounding 85 
factors and/or the ethical constraints of recruiting large number of pregnant women into clinical 86 
studies. With the aid of PBPK modelling techniques, these factors can be investigated separately 87 
to suggest the effect the impacts can make on the antimalarial therapy clinically.  88 
In this study, through virtual clinical trials simulations, we investigate the impact changes in PQ 89 
plasma concentrations in the absence and presence of ARV-mediated DDIs in three malaria-90 
specific geographical regions (Thailand, Papua New Guinea and Sudan) pregnant population 91 
groups, whereby changes in biochemical and haematology were incorporated into the design of the 92 
population groups.  93 
 94 
95 
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2.  METHODS 96 
All population based PBPK modelling was conducted using the virtual clinical trials simulator 97 
Simcyp (Simcyp Ltd, a Certara company, Sheffield, UK, Version 16). 98 
2.1 Model development 99 
A four-stage stepwise approach was employed for model development (Figure 1) which is fully 100 
described in the supplementary materials and briefly summarised below.   101 
2.1.1 Base model development (Step 1) 102 
The base model was developed from two reported studies of PQ dosed in fasted Caucasian healthy 103 
volunteers (Ahmed et al., 2008; Sim, Davis, & Ilett, 2005).  Given the high lipophilicity and 104 
expected wide-spread tissue distribution of PQ, a full PBPK model was employed for all model 105 
simulations.   106 
2.1.2 Non-pregnant malaria population groups (Step 2) 107 
To assess the predictive performance of the model in non-Caucasian non-complicated malaria 108 
population groups, we identified four studies where PQ was dosed to non-pregnant females in 109 
Thailand (Rijken et al., 2011; Tarning et al., 2012) [Tarning et al 2008 (Tarning et al., 2008) was 110 
excluded from thus study due to the difficulty in obtaining individual data points for the study 111 
duration], Papua New Guinea (Benjamin et al., 2015) and Sudan (Hoglund et al., 2012).  The 112 
‘Healthy Volunteer’ (HV) population group within Simcyp was adapted.  In order to address the 113 
differences in patient demographics (primarily body weight) and biochemistry (haematocrit/plasma 114 
proteins) between healthy-subjects and malaria-subjects (see supplementary materials Table S1).115 
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2.1.3 Pregnant malaria population groups (Step 3) 116 
The ‘Pregnancy’ population group within Simcyp was adapted (see supplementary materials) to 117 
create ‘Malaria-Pregnancy’ population groups based upon the three regional populations 118 
originating from the four clinical studies highlighted in section 2.1.2.  These studies also detailed 119 
the pharmacokinetics of PQ in pregnant women and this was used as a basis to further validate the 120 
‘Malaria-Pregnancy’ population groups.  Final model parameters for PQ are detailed in 121 
supplementary materials Table S2. 122 
2.1.4. ‘What-If’ scenarios (Step 4) 123 
To assess ‘What-If’ scenarios (Figure 1), case studies were included, in order to demonstrate the 124 
impact of possible drug-drug interactions mediated by efavirenz (EFV) or ritonavir (RTV); the 125 
former was selected due to the potential for CYP3A4 induction and the latter for its CYP3A4 126 
inhibitory effects.   127 
2.1.4.1  Efavirenz/Ritonavir-mediated drug-drug interactions 128 
Validation of DDIs mediated by ART was considered through the only published DDI study 129 
available (Kajubi et al., 2017b) with EFV and PQ in a Ugandan population group.  A Ugandan 130 
population group was developed (see supplementary materials for details) and the trial design was 131 
replicated for the three arms of the study within the reported trial, namely non-pregnant women 132 
with no-DDI, pregnant women with no-DDI and pregnant women with a DDI scenarios, in order 133 
to compare the ability of the PQ PBKP model to capture the extent of the reported DDIs. 134 
Subsequently, DDIs were simulated in a 10x10 virtual clinical trial with each population group 135 
described previously (see section 2.1.2).  A standard daily dose approach was employed for EFV 136 
(600 mg once daily) and RTV (100 mg twice daily, in line with ritonavir/lopinavir combination 137 
dosing of 100mg/400mg twice daily) with EFV/RTV dosed for 14 days and PQ dosed on days 3,4 138 
and 5 (10 mg/kg PQ base).  The malaria-pregnancy population groups were redefined during the 139 
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simulation duration on a daily basis to account for physiological/biochemical changes, and studies 140 
conducted across gestational weeks (GW) 10 to 40.  EFV and RTV are pre-validated compounds 141 
developed by Simcyp and included into the Simcyp Simulator® compound library. The RTV 142 
compound file has been widely used as a CYP3A4 inhibitor in mechanistic modelling (Colbers, 143 
Greupink, Litjens, Burger, & Russel, 2016; Hyland, Dickins, Collins, Jones, & Jones, 2008; 144 
Kaspera et al., 2014; Marsousi et al., 2016; Wang, 2010), and compound-specific parameters and 145 
validation data for the use of EFZ as a CYP3A4 and 2B6 inducer within the Simcyp Simulator®, 146 
have recently been published (Ke, Barter, Rowland-Yeo, & Almond, 2016). 147 
2.1.4.2. Human serum albumin 148 
Human serum albumin (HSA) concentrations was set at 20 g/L and 50 g/L within population 149 
groups, to mimic the reduction in serum albumin reported at different stages of malaria infection, 150 
with 20 g/L representing severe malaria (Sagaki et al., 2013) .  The Simcyp ‘Pregnancy’ population 151 
includes a description for alterations in HSA during pregnancy and the baseline initial HSA 152 
concentration was fixed at the aforementioned concentrations. 153 
2.1.4.3. Gestational week 154 
The impact of gestation week on PQ pharmacokinetic during EFV/RTV-mediated DDI was further 155 
assessed at weeks 10, 20 and 30 for all population groups.   156 
2.2 Predictive performance 157 
Although no uniform criterion has been accepted for defining an ‘optimal’ predictive performance 158 
range, a prediction to within 2-fold of the observed data is generally accepted in this context [40] 159 
and was employed as our criterion for Cmax and AUC comparisons to those clinically reported.  For 160 
EFV/RTV DDI simulation, as the clinical efficacy of PQ is determined by its day-7 concentration 161 
(post-first dose) of 30 ng/mL (Price et al., 2007), the impact of a DDI of PQ pharmacokinetics was 162 
assessed by direct analysis of the day-7 concentration. 163 
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2.3 Data analysis 164 
Unless otherwise stated, all simulations of plasma concentration-time profiles were presented as 165 
arithmetic mean and 5-95th percentiles.  Reported concentration-time profiles from clinical studies 166 
were digitally retrieved using the WebPlotDigitizer v3.10 [41] and superimposed onto simulated 167 
profiles for visual predictive checks.     168 
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3. RESULTS  169 
3.1. Healthy volunteer: base model development (Step 1) 170 
The initial model development for health-volunteer (Caucasian) subjects focussed on addressing 171 
model validation to recover appropriate absorption kinetics coupled with an appropriate prediction 172 
of steady state volume of distribution (Vss) and CYP3A4 and CYP2C8-mediated metabolic 173 
clearance (see supplementary materials).  The resultant model was found to be appropriate to 174 
capture Cmax and tmax and resulted in a broadly consistent simulated Cmax (21.5 ng/mL ± 9.2 ng/mL), 175 
tmax (5.3 hours) and AUC (AUC0-24: 384.2 ng h/mL ± 145.9 ng h/mL; AUC0-last: 3207.3 ng h/mL ± 176 
1121 ng h/mL) when compared to Ahmed et al (Ahmed et al., 2008) (Cmax: 41.6 ng/mL ± 29.5 177 
µg/L; tmax: 4.0 hours; AUC0-24: 393 ng h/mL ± 149 ng h/mL; AUC0-last: 2312 ng h/mL ± 790 ng 178 
h/mL) (Figure 2A) and Sim et al (Sim et al., 2005) (Cmax [range]: 21.0 µg/L [14-31.4 µg/L]; tmax: 179 
6.8 hours [2.1-11.5 hours]; AUC0-last: 2818 µg h/L [1566-5070 µg h/L]) for a 500 mg PQP dose 180 
(Figure 2C).  For a higher 1500 mg PQP dose, consistent simulated Cmax (76.1 ng/mL ± 69 ng/mL), 181 
tmax (5.1 hours) and AUC (AUC0-24: 1243 ng h/mL ± 193.8 ng h/mL; AUC0-last: 9065 ng h/mL ± 182 
1299 ng h/mL) were simulated when compared to Ahmed et al (Ahmed et al., 2008) (Cmax: 147 183 
ng/mL ± 110 µg/L; tmax: 2.5 hours; AUC0-24: 1418 ng h/mL ± 775 ng h/mL; AUC0-t: 6399 ng h/mL 184 
± 2067 ng h/mL) (Figure 2B). 185 
These predictions supported the successful model development in healthy-volunteer population 186 
groups for fasted single dose studies only.   187 
 188 
3.2 Non-Caucasian, non-pregnant malaria population groups (Step 2) 189 
In order to assess the predictive performance in multi-dose studies, three-population groups were 190 
developed for Thailand, Papua New Guinea and Sudan females based on published clinical studies 191 
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within these groups, under conditions of standard multi-dose regimens (10 mg/kg PQ base once 192 
daily for 3 days) (Figure 3). 193 
For all population groups, the majority of estimated parameters (Table 1) fell within 2-3 fold of the 194 
reported metrics (Table 2). Notability however, for the Thailand population group, the predicted 195 
increase in median Cmax following each dose was only moderately correlated with that reported by 196 
Rijken et al (Rijken et al., 2011) (Figure 3).  However, the clinical end-point marker of successful 197 
antimalarial therapy (day 7 concentration) (Price et al., 2007) were all simulated (Table 1) to with 198 
2-fold of the reported clinical measures (Table 2), in addition to day 14 and day 28 concentrations.  199 
Furthermore, the model predictions were also able to capture the differences in day 7 concentration 200 
across population groups, despite similar dosing strategies, e.g. Thai 24.74 ng/mL (4.42-64.93 201 
ng/mL) vs. Sudanese 34.0 ng/mL (6.8-86.7 ng/mL) population groups.  A one-way ANOVA 202 
indicated statistical differences in the median day 7 concentrations, when comparing all 4 predicted 203 
population studies, with the Sudanese population group demonstrating a statistically higher median 204 
Cmax (p = 0.0415) compared to the other population groups. 205 
This highlighted the successful creation of sub-population group’s validation in each population 206 
group. 207 
 208 
3.3 Non-Caucasian, pregnant malaria population groups (Step 3) 209 
The PBPK model was further adapted to evaluate PQ pharmacokinetics in non-Caucasian pregnant 210 
population groups (Figure 4).  For all population groups, the majority of estimated parameters 211 
(Table 3) fell within 2-fold of the reported metrics (Table 4), with predictions of the median day 7, 212 
14 and 28 concentrations all simulated to with 2-fold of the reported clinical measures (Table 4).  213 
These predicted point markers were not significantly different than those for non-pregnant subjects 214 
(p > 0.05) (Tables 1 and 2) 215 
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A one-way ANOVA indicated statistical differences in the median day 7 concentrations, when 216 
comparing all 4 predicted population studies, with the Sudanese population group demonstrating a 217 
statistically higher median Cmax (p = 0.0392) compared to the other population groups (Figure 4).  218 
However, when comparing non-pregnant to pregnant population groups, no significant difference 219 
in the median day 7 concentration was identified for each population. Further, predicted half-life 220 
in pregnancy population groups were significantly different (p < 0.01 for all population groups [t-221 
test]) from those in non-pregnancy population groups (Table 3). 222 
This highlighted the successful creation of sub-population group’s validation in each population 223 
group. 224 
 225 
3.4 ‘What-If’ scenarios (Step 4) 226 
To evaluate and validate the impact of ART on PQ systemic exposure, the only known recent study 227 
investigating the impact of ART (efavirenz) on PQ systemic exposure in Ugandan pregnant women  228 
(Kajubi et al., 2017b) was replicated, following creation of a Uganda pregnancy-malaria population 229 
group (see supplementary materials) where EFV was orally dosed at 600 mg once daily (see 230 
supplementary materials Figure S1).  The predicated day 7, 14 and 21 PQ concentrations were all 231 
within 2-fold of that reported by Kajubi et al (Kajubi et al., 2017b), with a similar approximate 50 232 
% decrease in the predicted mean day 7 concentrations (No EFV: 20.5 ng/mL; EFV: 9.2 ng/mL) 233 
(see supplementary materials Table S3). Furthermore, our predicted AUC0-d21 was within 2-fold of 234 
that reported by Kajubi et al (this study: 0.51; Kajubi: 0.62).   235 
 236 
3.4.1 The impact of change in HSA on the extent of ART-DDIs 237 
In all population groups (absence and presence of a DDI) an increase in HSA from 20 g/L to 50 238 
g/L significantly increased the median day 7 (total) plasma concentration of PQ (Figure 5).  This 239 
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was associated with a significant increase in the number of subjects with a day 7 concentration > 240 
30 ng/mL in the absence of an ART (Thailand: 8 to 45, p = 0.007; PNG: 11 to 53, p = 0.00009; 241 
Sudan: 9 to 49, p = 0.0006), and in the presence of EFV (Thailand: 7 to 48, p = 0.006; PNG: 4 to 242 
24, p = 0.0003; Sudan: 1 to 16, p = 0.0005) or RTV (Thailand: 41 to 80, p = 0.0009; PNG: 49 to 243 
85, p = 0.0008; Sudan: 47 to 80, p = 0.00003) (Figure 5). 244 
Additionally, the presence of EFV or RTV significantly reduced or increased, respectively, the day 245 
7 PQ concentration across all population groups, however the overall impact of the DDI across 246 
population groups for both EFV and RTV were broadly similarly (Figure 5).  This resulted in a 247 
similar number of subjects attaining a day 7 concentration ≥ 30 ng/mL except for the Sudanese 248 
population with a EFV-mediated DDI, where a statistically significant difference in the median day 249 
7 concentration across the three population groups was identified (One-Way ANOVA, p = 0.0023). 250 
 251 
3.4.3 The impact of gestation on the extent of an ART-mediated DDI 252 
In the absence of an ART-mediated DDIs, the median predicted day 7 concentration was broadly 253 
consistent across all gestational weeks investigated (Thailand: 20.2-21.2 ng/mL; PNG: 22.5-23.5 254 
ng/mL); Sudan: 25.1-26.2 ng/mL) and demonstrated no significant difference across gestational 255 
weeks within the same population group (Figure 6). 256 
In the presence of EFV, a significant decrease in PQ concentrations (p < 0.0001) was simulated 257 
across all gestational weeks within each population group (Thailand: 9.8-11.3 ng/mL; PNG: 13.2-258 
21.5 ng/mL; Sudan: 15.4-18.3 ng/mL), except for gestational week 40 with the PNG population 259 
group (Figure 6).  In the presence of RTV, a significant increase in PQ concentrations (p < 0.0001) 260 
were simulated across all gestational weeks within each population group (Thailand: 34.2-37.9 261 
ng/mL; PNG: 40.7-42.2 ng/mL; Sudan: 41.3-46.1 ng/mL).  Furthermore, a trend in increasing 262 
median concentration with increasing gestational week was observed for all population groups, 263 
although this was not statistically significant (Figure 6). 264 
BDD-17-0050.R1 
 
4. DISCUSSION 265 
The treatment of malaria in special populations, such as pregnant women and young children, is 266 
complicated by the ‘moving-target’ nature of such population groups and their associated reduced 267 
immune function with which to resist the individual impact and spread of malaria.  Attempting to 268 
address the problem of AMT in malaria endemic areas requires careful consideration of the disease 269 
pathophysiology in those population groups which may in turn impact upon the efficacy endpoint 270 
of the antimalarial treatment.  With the aid of PBPK modelling techniques, these factors can be 271 
investigated separately to suggest the effect specific impacts can make on antimalarial therapy 272 
clinically.  Hence, the applied 4-stage workflow model (Figure 1) was aimed at developing and 273 
validating a PBPK model to assess the pharmacokinetics of PQ during pregnancy, as well as under 274 
conditions of altered serum albumin (mimicking severe malaria), and during potential DDIs; these 275 
were mediated by common ARTs available for use in pregnant women (efavirenz and ritonavir). 276 
Despite the advantages of PBPK/mechanistic modelling, the application of modelling 277 
approaches to the prediction of plasma concentration profiles has largely been based around 278 
systems-parameters derived from Caucasian healthy subjects.  The base model development in step 279 
1 followed this similar approach, but only to identify and optimise parameters for single dose PQ 280 
studies.  A common feature of many antimalarials are the large variability in absorption kinetic 281 
processes, represented by a highly variable Cmax, and it was important to capture this, where 282 
possible (Borrmann et al., 2010; Sim et al., 2005; Tarning et al., 2014; White, 2013). To this end, 283 
in the absence of appropriate in-vitro Caco-2 derived passive permeability (Papp) measures for PQ, 284 
we applied a first-order absorption model with final estimates of 0.50 for fa and 0.45 h-1 for ka 285 
which were able to recover the Cmax and tmax compared to the single-dose studies (Figure 2). 286 
However, to capture the range of reported values (e.g. Cmax: 14-31.5 µg/L and tmax:  2.1-11.7 h) a 287 
50 % CV was applied.  It should be noted that an inclusion of a transit absorption model, such as 288 
the Simcyp ADAM module, may improve predictions (Tarning et al., 2012) but the lack of 289 
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appropriate in-vitro permeability measures makes this less attractive over a first order model.  The 290 
development of the base model was successful for single dose studies.   291 
Malaria is endemic in developing countries and this is reflecting by the availability of reported 292 
clinical studies we identified where PQ was administrated to pregnant and non-pregnant women 293 
from studies conducted with subjects from Thailand (Rijken et al., 2011; Tarning et al., 2012), 294 
Sudan (Hoglund et al., 2012) and Papua New Guinea (Benjamin et al., 2015). Application of the 295 
‘Healthy-Volunteer’ population group to simulate PQ pharmacokinetic would not be appropriate 296 
given the difference in adult age across these geographic regions (Walpole et al., 2012) and 297 
therefore custom age-weight relationships (Hayes et al., 2015) were generated for each population 298 
group to develop non-pregnant and pregnant populations from these regions, which incorporated 299 
alterations in blood parameters (haematocrit, human serum albumin and alpha-1-acidic 300 
glycoprotein) (see supplementary materials Table S1).  Change in haematological biochemistry are 301 
also common in malaria and it plays a major role in pathogenesis (Bakhubaira, 2013; Maina et al., 302 
2010; van Wolfswinkel et al., 2013). From a pharmacokinetic perspective, such changes are likely 303 
impact upon the blood:plasma ratio, but more importantly the unbound fraction, a key driver for 304 
the prediction of clearance, Vss and the DDIs. 305 
The development of appropriate systems-based population groups, specific to the study design is 306 
important and highlighted by the stark differences in body weights compared to ‘Healthy 307 
Volunteer’ population.  Using the customised age-weigh relationships for malaria population (see 308 
supplementary material), body weight for Thai (49.65 ± 7.13 kg), PNG (58.32 ± 12.2 kg) and Sudan 309 
(53.2 kg ± 14.46 kg) were generally consistent and significant difference (p < 0.01) from a standard 310 
‘Healthy Volunteer’ population group giving an average weight of 66.7 ± 13.1 kg.  As dosing for 311 
many AMT is based on body weight, this may have a direct effect on the dose administered and 312 
the resultant determination of endpoint concentrations (Terlouw, Courval, et al., 2003; Terlouw, 313 
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Nahlen, et al., 2003), particularly considered dosing in many developing countries is based on age 314 
as a surrogate for body weight, in situations where weight facilities are unavailable. 315 
Further, the inclusion of potential alterations in biochemistry- based changes during pregnancy or 316 
because of a disease state are important if they are thought to directly impact upon the resultant 317 
pharmacokinetics of AMT.  Haematological alterations are common in malaria and a marker of the 318 
severity of malaria is often determined from changes in serum albumin. Equally, albumin binding 319 
is a direct driver for the free fraction of drugs, and any alterations in this may directly impact upon 320 
drug distribution and metabolic pathways.  Indeed, the stark difference in HSA in Sudanese (45.5 321 
g/L) and Thai (33.7 g/L) illustrates this difference across population groups (see supplementary 322 
materials Table S1). 323 
For the three population groups developed, model predictions of key pharmacokinetics metrics 324 
were within 2-fold of those reported and illustrate the successful prediction of PQ in non-pregnancy 325 
(Table 1) (Figure 3) and pregnant women (Table 3; Figure 4).  Notably, no significant differences 326 
in key pharmacokinetic parameters, including day 7 concentrations,  were observed between non-327 
pregnant or pregnant population groups, suggesting the systemic exposure of PQ is relatively 328 
unchanged between the two groups and concurs with other reports of unchanged PQ 329 
pharmacokinetics in non-pregnant and pregnant populations (Adam et al., 2012; Rijken et al., 2011; 330 
Tarning et al., 2012).  However, model predictions were less successful at predicting the 331 
interindividual variability in the range of Cmax for population groups for each dosing period (Figure 332 
3 and 4).   This may be partially due to  poor control of food intake during the trial study, e.g. 333 
Tarning et al (2012) (Tarning et al., 2012),   but may also be a feature of the spare collection points 334 
around the expected Cmax for each dosing day compared to the much richer collection over the 335 
longer elimination phases (Tarning et al., 2012).  Further, the larger predicted Cmax for each dosing 336 
period could be a result of the splanchnic blood flow (as a result of increased cardiac out) seen in 337 
pregnancy (Dawes & Chowienczyk, 2001), and which is altered using ‘Pregnancy’ population 338 
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groups in Simcyp, and hence represent a slight increase in the bioavailability of PQ (Tarning et al., 339 
2012). 340 
During pregnancy, the activity of CYP3A4 is also known to increase (Little, 1999), directly 341 
impacting upon the metabolic clearance of any CYP3A4 substrates.  In our simulations, increasing 342 
gestational week had a noticeable impact of the terminal elimination of the PQ (see supplementary 343 
materials Figure S2), as quantified by a decrease in the terminal elimination half-life of PQ during 344 
pregnancy populations (Table 3) compared to non-pregnancy populations (Table 1). 345 
Having established a working PBPK for PQ in pregnant females, the importance of the risk of DDIs 346 
was next assessed.  The only existing study assessing the risk of DDI with PQ and antiretroviral 347 
(efavirenz) was recently published by Kajubi et al (Kajubi et al., 2017b), and demonstrated a 40% 348 
reduction in AUC0-21d along with a 50 % reduction in day-7 concentrations, highlighting the 349 
potential risk EFV-mediated DDIs pose, and our model was able to recapitulate these changes (see 350 
supplementary materials Figure S1).  As EFV is known to induce CYP3A4, the reduction in AUC 351 
and day-7 concentration is likely to be a result of this effect (Hariparsad et al., 2004). Further, this 352 
effect would be augmented by the induction of CYP3A4 itself during pregnancy, as noted for other 353 
drugs (Costantine, 2014; Dawes & Chowienczyk, 2001), and therefore would likely reduce day-7 354 
concentrations below the clinical efficacy end-point of 30 ng/mL (Price et al., 2007).  Indeed, our 355 
model simulation demonstrated the impact of this in non-pregnant, pregnant and pregnant +EFV 356 
populations, demonstrating the additive effect of EFV-mediated DDI and pregnancy-related 357 
induction of CYP3A4 expression (see supplementary materials Figure S1). 358 
Although pregnancy has been associated with a reduction in haematological parameters, e.g. human 359 
serum albumin (decrease by 1% at week 8 and 12% at week 32 (Murphy, Scott, McPartlin, & 360 
Fernandez-Ballart, 2002)), the impact of such changes on the pharmacokinetics of highly bound 361 
drugs is not well characterised in malarial infected subjects.  Further, as demonstrated by the 362 
development of specific populations, the overall haematological levels are often reduced in such 363 
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populations.  It has also been speculated that P. falciparum plays a major role in proteolysis of 364 
albumin (El Tahir, Malhotra, & Chauhan, 2003; Kolakovich, Gluzman, Duffin, & Goldberg, 1997).  365 
Further, previous reports have demonstrated alteration in fuplasma for quinine (Mansor et al., 1991) 366 
and halofantrine (Cenni, Meyer, Brandt, & Betschart, 1995) during the progression of malaria.  In 367 
attempting to assess the impact of potential changes in human serum, albumin on the overall extent 368 
of ART-mediated DDIs (via assessing change in PQ day 7 concentration), we set the HSA 369 
concentration to 20 g/L (severe malaria) and 50 g/L (healthy subjects).  In all cases (absence and 370 
presence of an ART) and in all population groups, the change from 20 g/L to 50 g/L had a direct 371 
on day 7 concentrations, leading to a statistically significant increase (Figure 5).  For all population 372 
groups developed, the reduction in HSA to 20 g/L, generally resulted in a statistically significant 373 
increase in PQ fuplasma (p < 0.001) which subsequently propagated to an increase in the hepatic 374 
clearance (p < 0.001), when compared to compared to healthy volunteer population groups.  This 375 
trend was also demonstrated under conditions of efavirenz/ritonavir exposure when compared to 376 
non-DDI studies (see table 5 for representative illustration in the Thailand non-pregnant 377 
population).  The impact of this combined reduction in baseline HSA concentration in malaria 378 
population coupled with the pregnancy-related reduction in HSA is important considering as it can 379 
directly impact upon the elimination of the drug. 380 
 381 
As expected, the impact of EFV and RTV on day 7 concentration were in-line with their function 382 
as CYP3A4 inducer (EFV) and inhibitors (RTV) resulting in a direct effect on day-7 383 
concentration following the interaction (Figure 5).  A reduction in AMT concentrations as a result 384 
of induction will lead to parasite recrudescence, as has been demonstrated for lumefantrine 385 
(Huang et al., 2012; WorldWide Antimalarial Resistance Network Lumefantrine, 2015), 386 
dihydroartemisinin (Lamorde et al., 2013) and piperaquine (Kajubi et al., 2017b).  Further, 387 
piperaquine is known to prolong QTc in a concentration dependant manner (Darpo et al., 2015), 388 
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and increased concentration following inhibition of metabolic clearance may potentially lead to 389 
QTc prolongation, as demonstrated with an adapted 2-day treatment with DHA-PQ (Manning et 390 
al., 2014). 391 
Physiological changes during gestation can result in significant changes in plasma volume, CYP 392 
expression and cardiac output (Costantine, 2014; Dawes & Chowienczyk, 2001), it would 393 
therefore be expected that significant changes in the pharmacokinetics would be expected during 394 
pregnancy.  We explored the impact of gestation on the predicted day-7 concentrations in the 395 
three pregnancy population groups. 396 
In all three populations, the baseline median day 7 concentration was consistent across all 397 
population groups and with increasing GW, approximately 20-26 ng/mL, with no significant 398 
differences when GW increased (Figure 6).  Given the long half-life of PQ, the impact of gestation 399 
on day 7 concentrations may not be significantly noticeable.  However, CYP3A4 activity is thought 400 
to increase during pregnancy, reaching a peak at approximately week 20-24 (Hebert et al., 2008; 401 
Hirt et al., 2006; Villani et al., 2006).  When considering the Thai population as an example, at 402 
baseline, GW20 corresponded with the lowest median day-7 concentration and highest hepatic 403 
CLint (week 17-27) (see supplementary materials Figure S3).  However the impact of this may be 404 
negligible given the long half-life and large volume of distribution of PQ (Adam et al., 2012; 405 
Benjamin et al., 2015; Rijken et al., 2011; Tarning et al., 2013).                                                       406 
 When ARVs were concomitantly dosed with PQ, statistically significant decreases (efavirenz) or 407 
increases (ritvonair) in PQ median day-7 concentrations were predicted, in-line with the role of 408 
EFV and RTV as inducer/inhibitors of CYP3A4 expression.  Surprisingly, there were no significant 409 
difference across GW for either ART, suggesting the magnitude of the DDI would be similar, 410 
irrespective of the gestation period of the mother.  Further, when considering the Thai population 411 
as an example, although each ART resulted in a significant change (p < 0.0001) in the hepatic 412 
CLint in the absence of ART (~290-320 L/h) and presence of ART (EFV: 1230-1271 L/h; RTV: 413 
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6.3-10.7 L/h), no significant differences across gestational weeks were simulated (see 414 
supplementary materials Figure S3).  Similarly, although each ART resulted in a significant change 415 
(p < 0.0001) in the oral CL in the absence of ART (~2000-2135 L/d) and presence of ART (EFV: 416 
4125-5142 L/d; RTV: 899-1239 L/d), no significant differences across gestational weeks were 417 
simulated (see supplementary materials Figure S3).  The resultant AUCratio (last dose-to-end) in the 418 
presence of EFV was consistent across GW 7 to 27 (0.56-0.58) but increased to 0.72 at GW 37 419 
(One way ANOVA, Tukey post hoc analysis p < 0.01) (see supplementary materials Figure S4). 420 
Similarly, inhibition results in an AUCratio across GW 7 to 27 (1.71-1.79) which decreased to 1.64 421 
at GW 37 (not significant) (see supplementary materials Figure S4).   422 
Further, median day 7 concentration in the absence and presence of an ART-mediated DDI were 423 
consistently higher in Sudanese population compared to Thai and PNG populations, and this can 424 
be attributed to the lower body-weight corrected doses administered to Thai subjects (see 425 
supplementary materials) coupled with the higher HSA concentrations in Sudanese populations 426 
(see supplementary materials table S1). 427 
Thus, although the impact of ARV on PQ pharmacokinetics in pregnancy may lead to treatment 428 
failure or an increase in the adverse effects, the overall effect and magnitude of the DDI during 429 
pregnancy is largely minimal, with little change in day-7 concentrations. 430 
It should be noted that the population groups developed altered only the age-weight relationships 431 
and haematological parameters, and reflecting changes predominantly malaria-infected subjects.  432 
Genetic polymorphisms in CYP2B6 are common (Haas et al., 2009; Lang et al., 2001; To et al., 433 
2009) and may impact upon the clearance of EFV and hence its ability to elicit a DDI, and CYP2B6 434 
population-based polymorphic changes were not incorporated into our customised population 435 
groups. Further, changes in the abundance of CYP-isozymes across population groups have also 436 
not been incorporated and this may enable better predictions of the terminal elimination phases for 437 
PQ across population groups (Bains, 2013).  It should also be noted that only one previous study 438 
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reported PQ metabolic pathways (Lee et al., 2012) and our assumption of the fraction metabolised 439 
by CYP3A4 and CYP2B6 of 0.99 and 0.01, alongside parameter estimated CLint, may be 440 
optimised at a later date with in-vitro metabolic clearance data to enhance the application of the 441 
model, when such data becomes available. 442 
Further, the complexity of diseases states which can present differently depending upon disease 443 
progress, as is common with malaria and HIV (Wanke et al., 2000), would dictate that  the 444 
developed population groups should address these different stages of disease progression.   Finally, 445 
the studies used for validation utilised two DHA-PQ combination formulation regimens, 446 
Eurartesim® (Sigma-Tau, Rome, Italy) or Artekin® (Holleykin Pharmaceutical Co., Guangzhou, 447 
China). However only Eurartesim® has gained Good Manufacturing Practice compliance, having 448 
being developed without the Medicines for Malaria Venture (MMV) (Ubben & Poll, 2013).  449 
Therefore, batch-to-batch variability in the manufacture of the Artekin® fixed-dose combination 450 
tablet, may lead to variability in disintegration/dissolution process resulting in altered absorption 451 
kinetics and this should be considered in the context of further validation of the absorption kinetics 452 
of the model development. Finally, estimates of PQ in-vitro Caco-2 permeability are currently 453 
lacking and therefore this precludes the application of the Simcyp ADAM model, to appropriately 454 
model the biopharmaceutics processes in greater mechanistic detail.  The modelling of the 455 
absorption phase of PQ pharmacokinetics may therefore be improved when such information 456 
becomes available. 457 
5. CONCLUSION 458 
The present PBPK model provides the ability to mechanistically predict the pharmacokinetic of PQ 459 
in non-pregnancy and pregnant women, whilst also considering possible population differences in 460 
malaria-HIV co-infected subjects.  The present model demonstrated that PQ pharmacokinetics in 461 
pregnancy is consistent and was relatively unchanged, compared to non-pregnant women and that 462 
the impact of ART-mediated DDIs can significantly alter the PQ pharmacokinetics, the magnitude 463 
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of which was generally consistent across GW.  Further adaptions of the model presented is 464 
warranted and would require further detailed collation of relevant physiological and biochemical 465 
alterations common to HIV/malaria patients and which would further enhance the clinical 466 
application of the proposed model.  467 
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LIST OF FIGURES 697 
 698 
Figure 1: A four-stage workflow approach for model development, validation and 699 
predictions 700 
 701 
Figure 2: The simulated plasma fasted single-dose concentration-time profile of piperaquine 702 
in healthy-volunteers 703 
(A) Simulation of PQ plasma concentration-time profile following a single oral dose of 500 mg 704 
PQP (left panel: open circles are observed mean points) and 1500 mg (right panel: open squares 705 
are observed mean points) to healthy volunteers (n=6). Observed data was obtained from Ahmed 706 
et al (2008) (Ahmed et al., 2008). (B) Simulation of PQ plasma concentration-time profile 707 
following a single oral dose of 500 mg PQP to healthy volunteers (n=8). Observed data is 708 
represented by open circles and represents the 3 individual subject concentration-time points only 709 
that were reported by Sim et al (2005)(Sim et al., 2005) out of a total study size of 8 subject.  Insert 710 
graphs illustrate plasma concentration profiles in the first 24-hours post-dosing.  Errors bars 711 
indicate either (A) lower SD at Cmax for observed data or (B) reported range of Cmax (vertical red 712 
line) or tmax (horizontal red line) values.  Solid lines represent population mean prediction with 713 
dashed lines representing the 5th and 95th percentiles of prediction. 714 
  715 
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Figure 3: The simulated plasma fasted multi-dose concentration-time profile of piperaquine 716 
in non-pregnant malaria-female subjects 717 
Multidose simulations of PQ (10 mg/kg base once daily for 3 days) were conducted on malaria-718 
non-pregnant female population groups (Thailand (Rijken et al., 2011; Tarning et al., 2012), Papua 719 
New Guinea (Benjamin et al., 2015) and Sudan (Hoglund et al., 2012), adapted from the ‘Healthy 720 
Volunteer’ population group with Simcyp with adaptations to the age-weight relationships and 721 
blood biochemistry and matching (where possible) the clinical trial design (subject numbers and 722 
age range) within Simcyp. Crosses indicate observed data obtained from reported individual subject 723 
plasma concentration-time profile lines, open circles indicated observed data sampling points 724 
obtained from individual plasma concentration points. Insert graphs illustrate plasma concentration 725 
profiles in the first 24-hours post-dosing.  Solid lines represent population median predictions with 726 
dashed lines representing the 5th and 95th percentiles of prediction. 727 
 728 
Figure 4: The simulated plasma fasted multi-dose concentration-time profile of piperaquine 729 
in pregnant malaria subjects 730 
Multidose simulations of PQ (10 mg/kg base once daily for 3 days) were conducted on malaria- 731 
pregnant female population groups (Thailand (Rijken et al., 2011; Tarning et al., 2012), Papua New 732 
Guinea (Benjamin et al., 2015) and Sudan (Hoglund et al., 2012), from, adapted from the 733 
‘Pregnancy’ population group within Simcyp with adaptations to the age-weight relationships and 734 
blood biochemistry and matching (where possible) the clinical trial design (subject numbers and 735 
age range). Crosses indicate observed data obtained from reported individual subject plasma 736 
concentration-time profile lines, open circles indicated observed data sampling points obtained 737 
from individual plasma concentration points. Insert graphs illustrate plasma concentration profiles 738 
in the first 24-hours post-dosing.  Solid lines (black: non-pregnant [for comparison]; red: pregnant) 739 
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represent population median prediction with dashed lines representing the 5th and 95th percentiles 740 
of prediction.   741 
 742 
Figure 5. The impact of changes in human serum albumin concentrations on the piperaquine 743 
median day 7 concentration in the absence and presence of an EFZ or RTV-mediated DDI 744 
Multidose simulations of PQP (10 mg/kg base once daily for 3 days) were conducted on malaria- 745 
pregnant female population groups (Thailand, Papua New Guinea and Sudan).  The human serum 746 
albumin concentration was fixed at 20 g/L or 50 g/L.  EFV (600 mg once daily) (red bars) or RTV 747 
(100 mg twice daily) (green bars) were orally dosed throughout the simulation time period (30 748 
days) with piperaquine dosed on days 10, 11 and 12. Box and whisker plots represent minimal, 25th 749 
percentile, median, 75th percentile and maximum values.  Dashed lines indicate the 30 ng/mL 750 
clinical efficacy cut-off. Numbers above the box and whisker are median values and the number 751 
(n) of subjects with a predicted concentration of over 30 ng/mL is indicated. Vertical drop-lines 752 
indicated statistical comparisons between 20g/L or 50 g/L simulation.  Asterisks above the 753 
maximum bar indicate statistical significance when compared to black (no DDI) simulations. ** p 754 
≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001. 755 
 756 
Figure 6. The impact of changes in gestational week on median day 7 PQ concentration in the 757 
absence and presence of a DDI mediated by EFZ (induction) or RTV (inhibition) 758 
Multidose simulations of PQP (10 mg/kg base once daily for 3 days) were conducted on malaria- 759 
pregnant female population groups (Thailand, Papua New Guinea and Sudan over gestational 760 
weeks (GW) 10, 20, 30 and 40.  EFV (600 mg once daily) or RTV (100 mg twice daily) were orally 761 
dosed throughout the simulation time period (30 days) with PQ dosed on days 10, 11 and 12. Box 762 
and whisker plots represent minimal, 25th percentile, median, 75th percentile and maximum values.  763 
Dashed lines indicate the 30 ng/mL clinical efficacy cut-off. Numbers above the box and whisker 764 
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are median values and the number (n) of subjects with a predicted concentration of over 30 ng/mL 765 
is indicated. Horizontal drop-lines indicate statistical comparisons between each GW in the absence 766 
and presence of the ART. ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001. 767 
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TABLES 768 
Table 1: Simulated PQ pharmacokinetics in non-Caucasian non-pregnant females 769 
 Thailand PNG Sudan 
 Rijken Tarning Benjamin Hoglund 
 Median 
 (Range) 
Median 
(Range) 
Median 
 (Range) 
Median 
(Range) 
     
Cmax 1
st (ng/mL) 66.14 (17.2-182.1) 64.59 (18.7-189.5) 87.70 (20.76-216.39) 92.15 (25.11-261.7) 
Cmax 2
nd (ng/mL) 85.25 (21.23-241.46) 88.17 (23.74-251.49) 116.15 (25.89-292.40) 116.8 (30.71-337.6) 
Cmax 3
rd (ng/mL) 98.5 (23.9-280.62) 99.2 (24.2-284.45) 134.6 (29.25-342.48) 134.6 (34.51-388.5) 
Tmax (h)     
Tmax 1
st (h) 4.80 (2.88-6.48) 4.81 (2.82-6.12) 4.67 (2.91-6.51) 3.84 (2.16-5.04) 
Tmax 2
st (h) 4.56 (2.64-6.01) 4.61 (2.54-6.32) 4.46 (2.72-6.06) 3.6 (2.16-4.8) 
Tmax 3
st (h) 4.56 (2.64-7.62) 4.62 (2.71-7.20) 4.39 (2.7-6.12) 3.6 (2.16-4.8) 
AUC0-24 (ng/mL.h) 998.64 (240-2830.8) 993.56 (248-2824.9) 1372.8 (296.83-3466.7) 1261.4 (318.24-3678.7) 
AUC24-48 (ng/mL.h) 1409.3 (324.5-4074.9) 1429.3 (331.5-4107.34) 1968.7 (404.8-5064.4) 1790.6 (436.08-5254.3) 
AUC 48-72 (ng/mL.h) 1712.4 (384-4945.9) 1762.1 (381-4995.2) 2378.4 (479.4-6175.7) 2194 (520.6-6383.8) 
AUC 0-∞ (µg/L.h)   21715 (4463-53645.8) 35201.3 (303.9-74180.6) 
Day 7 Conc. (ng/mL)  24.74 (4.42-64.93) 25.11 (4.21-65.14) 29.17 (5.31-80.85) 34.0 (6.8-86.7) 
Day 14 Conc. (ng/mL) 17.01 (3.17-41.63) 16.78 (3.22-42.99) 18.75 (3.67-49.9) 24.2 (5.3-54.9) 
Day 28 Conc. (ng/mL) 12.03 (2.34-26.28) 11.63 (2.23-27.27) 11.70 (2.05-26.80) 17.5 (4.02-38.7) 
Half-life (d) 27.3 (21.3-40.9) 28.5 (20.8-39.8) 18.3 (16.1-23.6) 32.1 (21.6-43.3) 
 770 
  771 
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Table 2: Literature reported PQ pharmacokinetics in non-Caucasian non-pregnant females  772 
 Thailand PNG Sudan 
 Rijken Tarning Benjamin Hoglund 
 Median 
 (Range) 
Median 
(IQR) 
Median 
 (Range) 
Median 
(Range) 
     
Cmax 1
st (ng/mL)  291 (194–362)  185 (109–363) 
Cmax 2
nd (ng/mL) 138 (39.3–328)    
Cmax 3
rd (ng/mL) 201 (58.2–455)    
Tmax (h)      309 (138–575)    
Tmax 1
st (h)  3.14 (2.84–3.84)  3.07 (1.65-4.64) 
Tmax 2
st (h)     
Tmax 3
st (h)     
AUC0-24 (ng/mL.h)     
AUC24-48 (ng/mL.h) 1480 (506–3,270)    
AUC 48-72 (ng/mL.h) 2400 (734–4,400)    
AUC 0-∞ (µg/L.h) 3660 (1,160–5,010)    
Day 7 Conc. (ng/mL)    23721 (21481–27951) 42700 (27100–68700) 
Day 14 Conc. (ng/mL) 31.8 (13.3–80.2) 28.8 (23.6–34.6)  60.7 (40.1-103) 
Day 28 Conc. (ng/mL) 19.5 (7.76–49.3)    
Cmax 1
st (ng/mL) 10.7 (3.70–31.4) 
 
10.3 (9.18–14.4)   16.1 (9.68-26.8) 
Half-life (d)a 4.78-39.9 22-26.1 20.3 20.9-33.3 
 773 
a Half-life is reported as a range or median 774 
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Table 3: Simulated piperquine pharmacokinetics in non-Caucasian pregnant females 775 
 Thailand PNG Sudan 
 
Rijken 
Median 
(Range) 
Tarning 
Median 
(Range) 
Benjamin 
Median 
(Range) 
Hoglund 
Median 
(Range) 
Cmax 1
st (ng/mL) 70.44 (33.56-153.08) 72.43 (31.92-167.89) 89.52 (38.20-175.42)  92.91 (41.04-202.38) 
Cmax 2
nd (ng/mL) 90.47 (46.02-204.60) 86.23 (50.61-214.36) 118.35 (25.82-237.95) 116.6 (55.6-263.53) 
Cmax 3
rd (ng/mL) 103.28 (53.95-237.19) 109.73 (53.54-264.38) 136.70 (61.99-276.93) 132.17 (65.25-303.4) 
Tmax (h)     
Tmax 1
st (h) 4.80 (2.9-7.68) 4.62 (3.1-7.98) 5.04 (2.9-8.16) 4.32 (2.64-6.96) 
Tmax 2
st (h) 4.56 (2.88-6.96) 4.86 (2.91-7.02) 4.8 (2.9-7.2) 4.08 (2.64-6.48) 
Tmax 3
st (h) 4.56 (2.88-6.96) 4.79 (2.83-7.11) 4.56 (2.9-6.96) 4.08 (2.64-6.24) 
AUC0-24 (ng/mL.h) 1036.3 (564.96-2429) 1135.2 (536.9-2532) 1399.4 (681.1-2850) 1249 (112.72-2974.32) 
AUC24-48 (ng/mL.h) 1450.3 (770.4-3482.4) 1424.1 (779.3-3599.8) 2002.1 (938.9-4127.52) 1745.3 (931.92-4229.76) 
AUC 48-72 (ng/mL.h) 1736.1 (912.5-4195.9) 1811.2 (964.9-4201.7) 2408.64 (1110.24-4977.1) 2424.96 (1114.1-5108.2) 
AUC 0-∞ (µg/L.h)   21633.6 (8383.9-42237.8) 30067.4 (15267-84201.1) 
Day 7 Conc. (ng/mL)  25.97 (10.87-52.59) 24.17 (11.03-53.13) 29.62 (12.2-57.7) 34.04 (15.13-70.60) 
Day 14 Conc. (ng/mL) 19.11 (7.88-39.46) 19.92 (8.24-40.11) 20.19 (7.89-38.8) 26.14 (11.31-56.55) 
Day 28 Conc. (ng/mL) 14.40 (5.63-31.20) 15.12 (5.91-39.97) 13.60 (4.82-27.2) 20.11 (7.94-45.62) 
Half-life (d) 19.4 (18.7-35.4) 19.9 (18.64-35.7) 26.3 (16.7-39.25) 24.7 (14.9-27.2) 
 776 
 777 
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Table 4: Literature reported piperquine pharmacokinetics in non-Caucasian pregnant females  779 
 Thailand PNG Sudan 
 Rijken Tarning Benjamin Hoglund 
 Median 
 (Range) 
Median 
(IQR) 
Median 
 (Range) 
Median 
(Range) 
     
Cmax 1
st (ng/mL)  216 (139–276)  102 (40.6-235) 
Cmax 2
nd (ng/mL) 71.6 (10.1–239)    
Cmax 3
rd (ng/mL) 136 (13.6–393)    
Tmax (h) 245 (53.4–798)    
Tmax 1
st (h)  3.04 (2.36–4.13)  1.48 (0.887-4.18) 
Tmax 2
st (h)     
Tmax 3
st (h)     
AUC0-24 (ng/mL.h)     
AUC24-48 (ng/mL.h) 869 (157–2,940)    
AUC 48-72 (ng/mL.h) 1710 (167–4,740)    
AUC 0-∞ (µg/L.h) 2750 (500–8,280)    
Day 7 Conc. (ng/mL)    35644 (29546–39541) 38000 (12400–100000)  
Day 14 Conc. (ng/mL) 25.9 (6.80–56.6) 22.7 (17.6–32.8)  55.4 (16.6-146) 
Day 28 Conc. (ng/mL) 16.7 (2.24–59.2)    
Cmax 1
st (ng/mL) 9.17 (5.14–47.6) 10.3 (8.06–14.9)   15.4 (4.85-38.6) 
Half-life (d)a 8.88-24.9 16.2-19.4 15.9 19.1-25.8 
 780 
a Half-life is reported as a range or median 781 
  782 
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Table 5: Impact of changes in blood biochemistry on hepatic clearance in the absence and presence of a efavirenz or ritonavir mediated drug-drug 783 
interaction for a representative population group (Thailand non-pregnant). 784 
  No DDI  Efavirenz Ritonavir 
  Healthy 20 g/L a 50 g/L a Healthy 20 g/L 50 g/L Healthy 20 g/L 50 g/L 
CLH (L/h) 8.41 ± 4.48 16.24 ± 6.91 7.06 ± 3.75 33.86 ± 10.95 46.91 ± 10.26 29.94 ± 9.43 2.62 ± 1.31 5.1 ± 2.35 1.94 ± 0.87 
fuplasma 
0.0139 ± 
0.0014 
0.0368 ± 
0.0037 
0.0135 ± 
0.0013 
0.0138 ± 
0.0016 
0.0375 ± 
0.0032 
0.0136 ± 
0.0014 
0.0137 ± 
0.0016 
0.0381 ± 
0.0031 
0.0138 ± 
0.0014 
HSA (g/L) b 45.28 ± 4.53 16.72 ± 1.73 46.81 ± 4.68 45.68 ± 4.66 16.62 ± 1.74 47.04 ± 4.63 45.16 ± 4.56 16.92 ± 1.72 47.21 ± 4.61 
 785 
a Pre-defined fixed mean human serum albumin (HSA) concentration. 786 
b Simcyp simulated population median HSA concentration 787 
Data represented as median ± standard deviation 788 
Healthy: Healthy Volunteer population group; CLH: hepatic clearance; fuplasma: unbound fraction in plasma; HSA: human serum albumin.  789 
